Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out

Scroll down and select country
MEBO TMAU TESTING CURRENTLY SUSPENDED INDEFINITELY

MEBO - UBIOME study 2018

'PRESS RELEASE'

NCT03582826
ClinicalTrials.gov

MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production
& PATM

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person

NO LONGER RECRUITING

Participation info : LINK English

MEBO Map Testing & Meetups


Full details : https://goo.gl/TMw8xu
want listed ? contact info@meboresearch.org

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts

MEBO TMAU Videos

Petitions

TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study
NCT02683876

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned


Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
EURORDIS and
NORD Member Organization
See RareConnect

Popular Posts (last 30 days)

Upcoming get-togethers


Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

London TMAU meeting with Prof Liz Shephard
19th Oct 11am - 1pm
St Mary's Hospital
Praed St, Paddington
London W2 1NY
click to read more
more details : karen.james@meboresearch.org

MEBO Research Clinical Trials

Click here to read details of the MEBO Clinical Trials
NCT03582826 - Ongoing not recruiting
Microbial Basis of Systemic Malodor and PATM Conditions (PATM)
United States 2018 - ongoing

NCT02683876 - Completed
Exploratory Study of Relationships Between Malodor and Urine Metabolomics
Canada and United States 2016 - ongoing

NCT03451994 - Completed
Exploratory Study of Volatile Organic Compounds in Alveolar Breath
United Kingdom and United States 2013 - ongoing

NCT02692495 - Completed
Evaluation of Potential Screening Tools for Metabolic Body Odor and Halitosis
United Kingdom 2009 - 2012

Saturday, August 20, 2011

New TMAU medical paper by Monell/Denver


Individuals Reporting Idiopathic Malodor Production: Demographics and Incidence of Trimethylaminuria
.
Wise PM, Eades J, Tjoa S, Fennessey PV, Preti G.

Monell Chemical Senses Center, Philadelphia, Pa.

Abstract
BACKGROUND:
Individuals with the metabolic disorder trimethylaminuria may sporadically produce malodors despite good hygiene. The psychosocial impact of trimethylaminuria can be considerable. However, trimethylaminuria is difficult to diagnose without specialized tests, in part because odor production is diet-dependent and malodors may not be present during medical examinations. Thus, the prevalence and demographics of trimethylaminuria remain unclear.

METHODS:
We tested 353 patients who had unexplained (idiopathic) malodor production for trimethylaminuria using a standard choline challenge. We also collected basic demographic information.

RESULTS:
Approximately one third of patients (118) tested positive for trimethylaminuria. Consistent with previous reports, women, particularly African American women, were significantly overrepresented among trimethylaminuria-positive patients. Of note, the same pattern was seen among trimethylaminuria-negative patients. Also consistent with previous reports, trimethylaminuria-positive women who were still menstruating tended to produce higher levels of trimethylamine within ±7 days of menses, although this trend was statistically marginal (P = .07).

CONCLUSION:
If our patient sample is representative of patients with idiopathic malodor, demographic information (race and gender) may not be useful in a differential diagnosis of trimethylaminuria. However, undiagnosed cases of trimethylaminuria may be fairly common among patients with idiopathic malodor. If so, choline challenge testing should be indicated for all such patients because trimethylaminuria is responsive to dietary and other treatments. We speculate that testing also might reveal cases of trimethylaminuria among those diagnosed with certain psychologic disorders, including olfactory reference syndrome.

Opinion of blog post author on the abstract

This is the abstract of a new paper on trimethylaminuria (TMAU) published ahead of print of the full paper. It could be a paper unfinished from a while ago, since it includes Susan Tjoa as an author, who sadly passed away a few years ago now.

It sounds a very useful paper as evidence for the case of testing most people with a long-time suspected malodor problem, including those diagnosed with the recently defined psychiatric 'disorder' known as 'olfactory reference syndrome'.

Special points of interest
The number of people who 'failed' the test (about 1/3). This was probably under the 'Denver TMAU test reference ranges', which does not seem to regard TMA level alone as significant (and hence is very unlikely to find anyone positive for 'TMA substrate overload' (the most common type of TMAU2).

A large number of the positive cases were women and especially African American women. This seems to be a reflection of the community, although perhaps women are more likely to test. Nevertheless, women of African American descent seem to be over-represented in the community. Another point of interest relating to females is that although 'TMAU' is regarded as possibly being worse around menses, this proved so in the study but only marginally so.

They suggest it may be worthwhile testing those diagnosed with 'olfactory reference syndrome' for TMAU. This has been a MEBO Research suggestion for a while now. It would make an excellent study and possibly mark the end of 'ORS'.

They used a choline challange for the test. It would be interesting to see the test done using the 'TMAU carrier test' protocol, which involves taking 600mg TMA load. Normal people would still be able to process almost all of 600mg of TMA, but those with 'no reserve capacity' (probably all 'carriers') would likely show up along with 'sufferers'. It should also be noted that the test only applies to trimethylamine and not any other FMO3 substrate. Currently only trimethylamine is accepted by the few labs that do TMAU testing as being the only FMO3 substrate that causes an odor in people.

0 comments:

Post a Comment